AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03015532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine, via injection
Study NCT04037085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
Study NCT02609477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Istradefylline 40, 80, 160 mg
Study NCT02609477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine 45 mg
Description: Phentermine 45 or 90 mg
Study NCT02609477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02609477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04238247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Basic Intervention
Description: A bilingual emergency department (ED)-based precision prevention intervention grounded in Self-Determination Theory. The Basic TCBD/ABCB intervention integrates one personalized counseling session based on principles of motivational interviewing (MI) and eHealth components including a tailored mobile-friendly educational website and short message service (SMS) text message communications with the goal of improving child passenger safety.~Participants receive monthly text message requests to submit photographs depicting the child as they usually travel. Feedback is provided via text message to correct any observed errors or misuse. Tailored informational and motivational text messages are sent twice each month.
Study NCT04238247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiny Cargo, Big Deal/Abróchame Bien, Cuídame Bien (TCBD/ABCB) Enhanced Intervention
Description: The Enhanced TBDC/ABCB Intervention includes a second motivational interviewing session. Basic Intervention text messages continue with an additional 1-2 tailored text messages per month.
Study NCT01964196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral administration
Study NCT01964196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03730363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
Study NCT01462279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: 200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
Study NCT02915120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real Pulsed Radiofrequency
Description: Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C.
Study NCT02915120 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed Radiofrequency
Description: Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
Study NCT04808700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of Episealer implant
Description: Follow-up and radiographic evaluation in patients who received an Episealer implant
Study NCT03604302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI Paradigms
Description: T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
Study NCT04334941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study NCT04334941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04334941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT01430312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid pre-foam formulation
Study NCT01430312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle pre-foam formulation
Study NCT01430312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT01430312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lauryl sulfate
Study NCT04537897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: BI474121
Study NCT02609477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01697345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Study NCT03520049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Study NCT03520049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01892852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
Study NCT02422901 — intervention group
Intervention type: DRUG
Intervention: vitamin C
Description: According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
Study NCT00230763 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: GSS questionnaire
Description: D0, D30 and D84
Study NCT01019551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Intensification
Description: Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
Study NCT01019551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunomodulation
Description: Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
Study NCT02455180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
Study NCT04779723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two Techniques of bariatric surgery
Description: We compared the 30 days outcomes in patients who underwent LSG procedure with those who underwent LRYGB
Study NCT02301091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Study NCT02301091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Study NCT02301091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
Study NCT02301091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirarubicin,mitomycin and lobaplatin
Description: They were cytotoxic drugs used in the TACE procedure.
Study NCT02301091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirarubicin,mitomycin and lobaplatin
Description: They were cytotoxic drugs used in the TACE procedure.
Study NCT02855983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Description: Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
Study NCT02855983 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fat Grafting
Description: Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
Study NCT00120874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized management of AD including caregiver training
Description: Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
Study NCT00120874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Patients receive 10 milligrams of memantine twice daily.
Study NCT00120874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Patients receive 10 milligrams of memantine twice daily.
Study NCT03406975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overstitch Endoscopic Suture System
Description: Endoscopic Sleeve Gastroplasty (ESG), an endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
Study NCT03406975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
Study NCT03406975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Standard low-calorie diet plan and moderate intensity life-style intervention of 150 minutes of aerobic exercise per week for 12 months.
Study NCT00230763 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: IOP
Description: D0, D30 and D84
Study NCT00230763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
Description: in the evening during 84 days
Study NCT00230763 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visual acuity
Description: D0 and D84
Study NCT01108055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Cycle of 28 days. Pazopanib: 800mg/day
Study NCT01108055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
Study NCT01450540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REMstar Auto A-Flex
Description: Standard CPAP
Study NCT01450540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified REMstar Auto A-Flex with AGPAP
Description: Modified device -Software upgrade to GP 12
Study NCT02354001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride
Description: 120mg daily- 1 capsule for 12 week trial
Study NCT02354001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 12 week trial - lactose
Study NCT00451087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leg press training
Description: quadriceps muscle strengthening. 30min/ 3times/ week
Study NCT00451087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isokinetic training
Description: quadriceps muscle training. 30 min/ 3 times/ week
Study NCT01115712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (to match pioglitazone 30 mg) once daily
Study NCT01115712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg once daily
Study NCT01115712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Hyperinsulinemic Euglycemic Clamp
Description: Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
Study NCT01115712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Hyperinsulinemic Euglycemic Clamp
Description: Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
Study NCT04995783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coral FRS test
Description: A novel clinical test to predict autoimmune medication response
Study NCT03114891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. In this study, we used administered theta burst TMS stimulation.
Study NCT03114891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task
Description: Subject completes a working memory task (Letter Nback) between the two rounds of theta burst stimulation.
Study NCT03114891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI-guided TMS target
Description: Administration of TMS to individualized targeting from the participant's fMRI scans. Our preliminary data suggest this target region is particularly effective at influencing the sgACC.
Study NCT03370263 — intervention group
Intervention type: DRUG
Intervention: Benlysta
Description: Benlysta will be administered intravenously or subcutaneously.
Study NCT01701063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
Study NCT01701063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: 50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
Study NCT01701063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg capsules or 40-mg/mL solution for oral administration
Study NCT03251807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin-block
Description: Functional treatment will be achieved using the Twinblock appliance
Study NCT03251807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIPUS (Low-intensity pulsed ultrasound)
Description: Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
Study NCT01839344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin 250 mg capsules; oral single dose of 2000 mg
Study NCT01839344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 100 mg tablet; oral single dose of 100 mg
Study NCT01839344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An oral single dose of a solid, colored empty capsule.
Study NCT04020952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: st.st 0.019×0.025 wire
Description: rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
Study NCT04020952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: st.st 0.016×0.022 wire
Description: rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
Study NCT04020952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: st.st 0.017×0.025 wire
Description: rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
Study NCT03151876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30 mg oral twice weekly for 2 weeks
Study NCT03151876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 6 mg/m2 intravenously daily for 5 days
Study NCT03151876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 mg/m2 intravenously twice weekly for 1 week
Study NCT03151876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg intravenously daily for 4 days
Study NCT03151876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Description: autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
Study NCT01422291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1 gr
Study NCT01422291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: 0.1mg/kg intravenous in 100 ml serum physiologic
Study NCT01422291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: 50 mg
Study NCT01422291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamole
Description: 1 gr
Study NCT04509453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGRATH laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
Study NCT04509453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGRATH laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using McGRATH video layngoscopy
Study NCT04509453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
Study NCT04509453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscopy
Description: Patients who underwent general anesthesia with LMA insertion by using classic Macintosh video layngoscopy
Study NCT04999501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance-type exercise training
Description: All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor A_2.4
Description: Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor B_2.4
Description: Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor C_2.4
Description: Use of Myblu e-cigarette with flavor C at 2.4% nicotine
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor D_2.4
Description: Use of Myblu e-cigarette with flavor D at 2.4% nicotine
Study NCT04429932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myblu flavor E_1.2
Description: Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine